Literature DB >> 25332956

Preoperative chemotherapy for locally advanced resectable colon cancer - a new treatment paradigm in colon cancer?

Zheng Zhou1, Halla S Nimeiri1, Al B Benson1.   

Abstract

Entities:  

Year:  2013        PMID： 25332956      PMCID： PMC4200631          DOI： 10.3978/j.issn.2305-5839.2013.01.01

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  26 in total

1.  Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.

Authors:  S Giacchetti; B Perpoint; R Zidani; N Le Bail; R Faggiuolo; C Focan; P Chollet; J F Llory; Y Letourneau; B Coudert; F Bertheaut-Cvitkovic; D Larregain-Fournier; A Le Rol; S Walter; R Adam; J L Misset; F Lévi
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

2.  Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

Authors:  J Philip Kuebler; H Samuel Wieand; Michael J O'Connell; Roy E Smith; Linda H Colangelo; Greg Yothers; Nicholas J Petrelli; Michael P Findlay; Thomas E Seay; James N Atkins; John L Zapas; J Wendall Goodwin; Louis Fehrenbacher; Ramesh K Ramanathan; Barbara A Conley; Patrick J Flynn; Gamini Soori; Lauren K Colman; Edward A Levine; Keith S Lanier; Norman Wolmark
Journal:  J Clin Oncol       Date:  2007-04-30       Impact factor: 44.544

3.  Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.

Authors:  Thierry André; Corrado Boni; Matilde Navarro; Josep Tabernero; Tamas Hickish; Clare Topham; Andrea Bonetti; Philip Clingan; John Bridgewater; Fernando Rivera; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

4.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Authors:  Christos S Karapetis; Shirin Khambata-Ford; Derek J Jonker; Chris J O'Callaghan; Dongsheng Tu; Niall C Tebbutt; R John Simes; Haji Chalchal; Jeremy D Shapiro; Sonia Robitaille; Timothy J Price; Lois Shepherd; Heather-Jane Au; Christiane Langer; Malcolm J Moore; John R Zalcberg
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

5.  Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.

Authors:  Carsten Bokemeyer; Igor Bondarenko; Anatoly Makhson; Joerg T Hartmann; Jorge Aparicio; Filippo de Braud; Serban Donea; Heinz Ludwig; Gunter Schuch; Christopher Stroh; Anja H Loos; Angela Zubel; Piotr Koralewski
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

6.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Authors:  Rafael G Amado; Michael Wolf; Marc Peeters; Eric Van Cutsem; Salvatore Siena; Daniel J Freeman; Todd Juan; Robert Sikorski; Sid Suggs; Robert Radinsky; Scott D Patterson; David D Chang
Journal:  J Clin Oncol       Date:  2008-03-03       Impact factor: 44.544

7.  Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial.

Authors: 
Journal:  Lancet Oncol       Date:  2012-09-25       Impact factor: 41.316

8.  Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial.

Authors:  David Sebag-Montefiore; Richard J Stephens; Robert Steele; John Monson; Robert Grieve; Subhash Khanna; Phil Quirke; Jean Couture; Catherine de Metz; Arthur Sun Myint; Eric Bessell; Gareth Griffiths; Lindsay C Thompson; Mahesh Parmar
Journal:  Lancet       Date:  2009-03-07       Impact factor: 79.321

9.  Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.

Authors:  Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Laurence Collette; Michel Praet; Ullrich Bethe; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

10.  A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer.

Authors:  S L Cheeseman; S P Joel; J D Chester; G Wilson; J T Dent; F J Richards; M T Seymour
Journal:  Br J Cancer       Date:  2002-08-12       Impact factor: 7.640
View more
  11 in total

1.  Outcomes of Neoadjuvant Chemoradiation in Patients with Gastro-esophageal Junction Adenocarcinoma: a Retrospective Cohort Study in Iran.

Authors:  Farshid Farhan; Reza Ghalehtaki; Shiva Mahdavi-Seresht; Alipasha Meysamie; Maisa Yamrali; Borna Farazmand; Negin Mohammadi; Ehsan Saraee; Mohammad-Reza Mir; Ali Mir; Marzieh Lashkari; Samaneh Salarvand; Ebrahim Esmati; Farhad Samiei
Journal:  J Gastrointest Cancer       Date:  2019-12

2.  Correlation Between Clinical and Pathologic Staging in Colon Cancer: Implications for Neoadjuvant Treatment.

Authors:  Ahmed N Dehal; Amanda N Graff-Baker; Brooke Vuong; Daniel Nelson; Shu-Ching Chang; David Y Lee; Melanie Goldfarb; Anton J Bilchik
Journal:  J Gastrointest Surg       Date:  2018-05-22       Impact factor: 3.452

3.  Does preoperative neoadjuvant chemotherapy impact short-term surgical outcomes in patients with locally advanced colon cancer?

Authors:  Ryan Silva; Mohammad Hamidi; Pamela Omesiete; Fawsia Osman; Casey Charlton; Shoujit Banerjee; Timothy Estrada; Valentine Nfonsam
Journal:  Int J Colorectal Dis       Date:  2021-05-08       Impact factor: 2.571

Review 4.  [Preoperative imaging for colorectal cancer: surgeons' perspective].

Authors:  I Iesalnieks; A Agha
Journal:  Radiologe       Date:  2019-09       Impact factor: 0.635

5.  Neoadjuvant Chemotherapy Improves Survival in Patients with Clinical T4b Colon Cancer.

Authors:  Ahmed Dehal; Amanda N Graff-Baker; Brooke Vuong; Trevan Fischer; Samuel J Klempner; Shu-Ching Chang; Gary L Grunkemeier; Anton J Bilchik; Melanie Goldfarb
Journal:  J Gastrointest Surg       Date:  2017-09-20       Impact factor: 3.452

6.  Neoadjuvant therapy in locally advanced colon cancer: a meta-analysis and systematic review.

Authors:  Chin Kai Cheong; Kameswara Rishi Yeshayahu Nistala; Cheng Han Ng; Nicholas Syn; Heidi Sian Ying Chang; Raghav Sundar; Soon Yu Yang; Choon Seng Chong
Journal:  J Gastrointest Oncol       Date:  2020-10

7.  The survival impact of preoperative FOLFOX for resectable locally advanced rectal cancer: the R-NAC-01 study.

Authors:  Nobuki Ichikawa; Shigenori Homma; Tohru Funakoshi; Masahiro Hattori; Masanori Sato; You Kamiizumi; Kazuyoshi Omori; Masaru Nomura; Ryoichi Yokota; Masahiko Koike; Hirofumi Kon; Keisa Takeda; Hiroyuki Ishizu; Shinichi Matsuoka; Kunihiro Hirose; Takahisa Ishikawa; Ryohei Murata; Hiroaki Iijima; Tadashi Yoshida; Nozomi Minagawa; Norihiko Takahashi; Akinobu Taketomi
Journal:  Surg Today       Date:  2022-01-05       Impact factor: 2.540

8.  Mid-term oncologic outcome of a novel approach for locally advanced colon cancer with neoadjuvant chemotherapy and surgery.

Authors:  J Arredondo; J Baixauli; C Pastor; A Chopitea; J J Sola; I González; J A-Cienfuegos; P Martínez; J Rodriguez; J L Hernández-Lizoain
Journal:  Clin Transl Oncol       Date:  2016-08-05       Impact factor: 3.405

Review 9.  Neoadjuvant chemotherapy in locally advanced colon cancer: a systematic review.

Authors:  J Arredondo; E Pastor; V Simó; M Beltrán; C Castañón; M C Magdaleno; I Matanza; M Notarnicola; B Ielpo
Journal:  Tech Coloproctol       Date:  2020-07-14       Impact factor: 3.781

10.  En Bloc Pancreaticoduodenectomy for Locally Advanced Right Colon Cancers.

Authors:  Cihan Ağalar; Aras Emre Canda; Tarkan Unek; Selman Sokmen
Journal:  Int J Surg Oncol       Date:  2017-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.